EQS-News: Gavi, The Vaccine Alliance: Dr Muhammad Ali Pate to become next Chief Executive Officer (CEO) of Gavi, the Vaccine Alliance 13.02.2023, 18:20 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Gavi, The Vaccine Alliance / Key word(s): Personnel
Gavi, The Vaccine Alliance: Dr Muhammad Ali Pate to become next Chief Executive Officer (CEO) of Gavi, the Vaccine Alliance

13.02.2023 / 18:20 CET/CEST
The issuer is solely responsible for the content of this announcement.


Dr Muhammad Ali Pate to become next Chief Executive Officer (CEO) of Gavi, the Vaccine Alliance

The Gavi (https://www.Gavi.org) Board has approved the appointment of Dr Muhammad Ali Pate as the Chief Executive Officer of the Vaccine Alliance following an extensive recruitment process; Dr Pate will assume the role as of 3 August 2023, replacing Dr Seth Berkley, who will step down after 12 years leading the Alliance; Dr Muhammad Ali Pate: “It will be my privilege to lead Gavi and continue to support countries to scale up critical routine immunisation programmes, reach more zero-dose children, expand access to new vaccines, transform primary health care systems, and help fight outbreaks and future pandemics.”

Gavi, the Vaccine Alliance announced today the appointment of Dr Muhammad Ali Pate as its new Chief Executive Officer. Dr Pate will be officially starting as CEO on 3 August 2023. A proven global health leader with experience at the national and international levels, Dr Pate will lead Gavi as it continues its work to support routine immunisation, outbreak response and COVID-19 vaccinations around the world.

Dr Muhammad Ali Pate, who was selected following a yearlong recruitment process personally overseen by the Chair of the Gavi Board, Professor José Manuel Barroso, will bring a wealth of experience to the role. A medical doctor trained in both internal medicine and infectious diseases, with an MBA from Duke University in the United States, Dr Pate served as Nigeria’s Minister of State for Health between 2011 and 2013. In this role, he led a flagship initiative to revive routine vaccinations and primary health care, chaired a presidential taskforce to eradicate polio and introduced new vaccines into the country.

While serving as Global Director for Health, Nutrition and Population of the World Bank and Director of the Global Financing Facility at the World Bank between 2019 and 2021, he led the Bank’s US$ 18 billion COVID-19 global health response and represented the Bank on various boards, including those of Gavi, the Global Fund, CEPI and UNAIDS. He is currently the Julio Frenk Professor of Public Health Leadership at Harvard Chan School of Public Health and has served on several health-focused boards and expert panels in the public, private and not-for-profit sectors during his career.

Commenting on the appointment, Professor Barroso said: “Dr Muhammad Ali Pate stood out in a field of world-class candidates. With his knowledge and experience of both national immunization programming and international emergency response and global finance, I am confident that Gavi will continue to build on its vision and mission, as well as navigate the many challenges and opportunities we will face.”

Dr Pate, whose appointment was confirmed today at an extraordinary meeting of the Gavi Board, said: “I’m deeply honoured to be joining Gavi as its incoming CEO. Gavi is one of the most impactful organisations in global health, a testament to the great work of the Alliance partners and Secretariat staff. It will be my privilege to lead it, building on the work of Dr Seth Berkley, and continue to support countries to scale up critical routine immunisation programmes, reach more zero-dose children, expand access to new vaccines, transform primary health care systems, and help fight outbreaks and future pandemics.”

Sitting CEO Dr Seth Berkley has led Gavi for more than half of its existence, making it a centrepiece within the global health landscape, including recently co-establishing COVAX to serve countries during the unprecedented COVID-19 pandemic, having so far shipped nearly 1.9 billion COVID-19 vaccine doses to 146 countries. Since Dr Berkley took the helm in 2011, the Alliance has averted 11.8 million future deaths (compared to 4.5 million between 2000 and 2010); and has helped immunise more than 676 million children – more than double the 305 million children reached between 2000 and 2010.

Thanks to Dr Berkley’s vision for health equity, Gavi has added a number of new vaccines to its portfolio during his tenure, including for HPV, polio, cholera and malaria, and in its current strategy cycle is focusing on reaching zero-dose children across marginalised communities. The Alliance also played an increasingly influential role in emergency response, developing vaccine stockpiles for diseases such as cholera and introducing innovative financing mechanisms to fund emergency purchase of Ebola and COVID-19 vaccines. The economic result of Gavi’s expansion of activities during his tenure has been profound, unlocking over US$ 160 billion of economic benefits compared to US$ 24 billion in its first ten years.

Commenting on Dr Pate’s appointment, Dr Berkley said: “Leading Gavi and helping the Alliance to continually surpass itself in terms of saving lives, protecting children and supporting countries during global health emergencies has been the greatest honour of my career. I am proud and humbled to have been part of what the Alliance has achieved, and I am confident in its future under Muhammad’s leadership: having worked with him during his time as Minister and at the World Bank, I know he understands intimately the landscape we work in and will be uncompromising in his drive for public health equity.”

Dr Berkley will continue to serve as CEO until 2 August 2023, while working with incoming CEO Dr Pate to ensure a smooth transition.

 

Distributed by APO Group on behalf of Gavi, The Vaccine Alliance.

 

Download image: https://apo-opa.info/3RXdwUw

 



13.02.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


1558625  13.02.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1558625&application_name=news&site_id=boersennews
Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer